Cargando…

EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome

BACKGROUND: Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal g...

Descripción completa

Detalles Bibliográficos
Autores principales: da Costa, Bruno Henrique Bressan, Becker, Aline Paixão, Neder, Luciano, Gonçalves, Paola Gyuliane, de Oliveira, Cristiane, Polverini, Allan Dias, Clara, Carlos Afonso, Teixeira, Gustavo Ramos, Reis, Rui Manuel, Bidinotto, Lucas Tadeu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists/The Korean Society for Cytopathology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288890/
https://www.ncbi.nlm.nih.gov/pubmed/35698739
http://dx.doi.org/10.4132/jptm.2022.04.22
_version_ 1784748548559994880
author da Costa, Bruno Henrique Bressan
Becker, Aline Paixão
Neder, Luciano
Gonçalves, Paola Gyuliane
de Oliveira, Cristiane
Polverini, Allan Dias
Clara, Carlos Afonso
Teixeira, Gustavo Ramos
Reis, Rui Manuel
Bidinotto, Lucas Tadeu
author_facet da Costa, Bruno Henrique Bressan
Becker, Aline Paixão
Neder, Luciano
Gonçalves, Paola Gyuliane
de Oliveira, Cristiane
Polverini, Allan Dias
Clara, Carlos Afonso
Teixeira, Gustavo Ramos
Reis, Rui Manuel
Bidinotto, Lucas Tadeu
author_sort da Costa, Bruno Henrique Bressan
collection PubMed
description BACKGROUND: Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal growth factor-like domain multiple 7 (EGFL7) expression and unfavorable outcome of pilocytic astrocytoma patients. The present study aims to analyze the prognostic potential of EGFL7 in GBM isocitrate dehydrogenase (IDH)-wildtype, using immunohistochemistry and in silico approaches. METHODS: Spearman’s correlation analysis of The Cancer Genome Atlas RNA sequencing data was performed. The genes strongly correlated to EGFL7 expression were submitted to enrichment gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Additionally, EGFL7 expression was associated with patient overall survival. The expression of EGFL7 was analyzed through immunohistochemistry in 74 GBM IDH-wildtype patients’ samples, and was associated with clinicopathological data and overall survival. RESULTS: In silico analysis found 78 genes strongly correlated to EGFL7 expression. These genes were enriched in 40 biological processes and eight KEGG pathways, including angiogenesis/vasculogenesis, cell adhesion, and phosphoinositide 3-kinase–Akt, Notch, and Rap1 signaling pathways. The immunostaining showed high EGFL7 expression in 39 cases (52.7%). High immunolabelling was significantly associated with low Karnofsky Performance Status and poor overall survival. Cox analysis showed that GBMs IDH-wildtype with high EGFL7 expression presented a higher risk of death compared to low expression (hazard ratio, 1.645; 95% confidence interval, 1.021 to 2.650; p = .041). CONCLUSIONS: This study gives insights regarding the genes that are correlated with EGFL7, as well as biological processes and signaling pathways, which should be further investigated in order to elucidate their role in glioblastoma biology.
format Online
Article
Text
id pubmed-9288890
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Society of Pathologists/The Korean Society for Cytopathology
record_format MEDLINE/PubMed
spelling pubmed-92888902022-07-29 EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome da Costa, Bruno Henrique Bressan Becker, Aline Paixão Neder, Luciano Gonçalves, Paola Gyuliane de Oliveira, Cristiane Polverini, Allan Dias Clara, Carlos Afonso Teixeira, Gustavo Ramos Reis, Rui Manuel Bidinotto, Lucas Tadeu J Pathol Transl Med Original Article BACKGROUND: Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal growth factor-like domain multiple 7 (EGFL7) expression and unfavorable outcome of pilocytic astrocytoma patients. The present study aims to analyze the prognostic potential of EGFL7 in GBM isocitrate dehydrogenase (IDH)-wildtype, using immunohistochemistry and in silico approaches. METHODS: Spearman’s correlation analysis of The Cancer Genome Atlas RNA sequencing data was performed. The genes strongly correlated to EGFL7 expression were submitted to enrichment gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Additionally, EGFL7 expression was associated with patient overall survival. The expression of EGFL7 was analyzed through immunohistochemistry in 74 GBM IDH-wildtype patients’ samples, and was associated with clinicopathological data and overall survival. RESULTS: In silico analysis found 78 genes strongly correlated to EGFL7 expression. These genes were enriched in 40 biological processes and eight KEGG pathways, including angiogenesis/vasculogenesis, cell adhesion, and phosphoinositide 3-kinase–Akt, Notch, and Rap1 signaling pathways. The immunostaining showed high EGFL7 expression in 39 cases (52.7%). High immunolabelling was significantly associated with low Karnofsky Performance Status and poor overall survival. Cox analysis showed that GBMs IDH-wildtype with high EGFL7 expression presented a higher risk of death compared to low expression (hazard ratio, 1.645; 95% confidence interval, 1.021 to 2.650; p = .041). CONCLUSIONS: This study gives insights regarding the genes that are correlated with EGFL7, as well as biological processes and signaling pathways, which should be further investigated in order to elucidate their role in glioblastoma biology. The Korean Society of Pathologists/The Korean Society for Cytopathology 2022-07 2022-06-15 /pmc/articles/PMC9288890/ /pubmed/35698739 http://dx.doi.org/10.4132/jptm.2022.04.22 Text en © 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
da Costa, Bruno Henrique Bressan
Becker, Aline Paixão
Neder, Luciano
Gonçalves, Paola Gyuliane
de Oliveira, Cristiane
Polverini, Allan Dias
Clara, Carlos Afonso
Teixeira, Gustavo Ramos
Reis, Rui Manuel
Bidinotto, Lucas Tadeu
EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
title EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
title_full EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
title_fullStr EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
title_full_unstemmed EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
title_short EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome
title_sort egfl7 expression profile in idh-wildtype glioblastomas is associated with poor patient outcome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288890/
https://www.ncbi.nlm.nih.gov/pubmed/35698739
http://dx.doi.org/10.4132/jptm.2022.04.22
work_keys_str_mv AT dacostabrunohenriquebressan egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT beckeralinepaixao egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT nederluciano egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT goncalvespaolagyuliane egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT deoliveiracristiane egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT polveriniallandias egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT claracarlosafonso egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT teixeiragustavoramos egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT reisruimanuel egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome
AT bidinottolucastadeu egfl7expressionprofileinidhwildtypeglioblastomasisassociatedwithpoorpatientoutcome